NEO vs. TNET, CARG, CNXC, DLO, PAGS, ATHM, ALIT, CLVT, WNS, and FA
Should you be buying NeoGenomics stock or one of its competitors? The main competitors of NeoGenomics include TriNet Group (TNET), CarGurus (CARG), Concentrix (CNXC), DLocal (DLO), PagSeguro Digital (PAGS), Autohome (ATHM), Alight (ALIT), Clarivate (CLVT), WNS (WNS), and First Advantage (FA). These companies are all part of the "business services" industry.
NeoGenomics vs. Its Competitors
NeoGenomics (NASDAQ:NEO) and TriNet Group (NYSE:TNET) are both business services companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.
TriNet Group has a net margin of 3.32% compared to NeoGenomics' net margin of -11.54%. TriNet Group's return on equity of 237.87% beat NeoGenomics' return on equity.
98.5% of NeoGenomics shares are owned by institutional investors. Comparatively, 96.8% of TriNet Group shares are owned by institutional investors. 2.4% of NeoGenomics shares are owned by company insiders. Comparatively, 37.1% of TriNet Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, NeoGenomics had 6 more articles in the media than TriNet Group. MarketBeat recorded 6 mentions for NeoGenomics and 0 mentions for TriNet Group. TriNet Group's average media sentiment score of 1.67 beat NeoGenomics' score of 0.42 indicating that TriNet Group is being referred to more favorably in the news media.
NeoGenomics has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, TriNet Group has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.
NeoGenomics presently has a consensus target price of $13.83, suggesting a potential upside of 86.68%. TriNet Group has a consensus target price of $96.67, suggesting a potential upside of 28.82%. Given NeoGenomics' stronger consensus rating and higher possible upside, research analysts clearly believe NeoGenomics is more favorable than TriNet Group.
TriNet Group has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than TriNet Group, indicating that it is currently the more affordable of the two stocks.
Summary
TriNet Group beats NeoGenomics on 9 of the 16 factors compared between the two stocks.
Get NeoGenomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeoGenomics Competitors List
Related Companies and Tools
This page (NASDAQ:NEO) was last updated on 7/2/2025 by MarketBeat.com Staff
Free NEO Stock Alerts